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Abstract
Radiation-induced morphea (RIM) of the breast is a rare complication of radiotherapy. It is
disfiguring, painful and defeats the purpose of achieving a good cosmesis in breast-conservation
surgery. This report describes a severe case of RIM in a breast cancer patient together with
photographic illustrations of the serial changes over time and histopathology slides. A review of the
literature is provided.
Introduction
Breast cancer is the most common cancer in women with
an incidence of 134 per 100,000 women in the United
Kingdom, and the incidence is still rising [1]. Radiother-
apy to the breast following breast-conservation surgery
reduces local recurrence and improves survival [2]. Radio-
therapy can cause acute skin reactions such as erythema or
moist desquamation, especially in women with large
breasts. Late side effects may include fibrosis (10%), skin
telangiectasia (10%), atrophy (8%) and pain (2%) [3].
We present a case of radiation-induced morphea (RIM) of
the breast, a rare late side effect of radiotherapy, with
serial changes in the appearance over a period of 3 and a
half years.
Case presentation
In October 2000, a 57-year-old Caucasian woman was
diagnosed with breast carcinoma following mammogram
screening. She had a wide local excision of the left breast
and axillary node sampling. Histology was reported as
T1N0 grade 1 invasive ductal carcinoma with clear resec-
tion margins. She was treated with tamoxifen 20 mg daily
and commenced on adjuvant radiotherapy to the left
breast and axilla. The radiotherapy dose was 40 Gy in 15
fractions using medial and lateral tangential fields of 5 MV
photons followed by 5 Gy in two fractions of 10 MeV elec-
tron boost to the tumour bed.
At the end of her radiotherapy treatment the patient devel-
oped acute radiotherapy reaction in the left inframam-
mary fold consisting of mild moist desquamation that
subsequently resolved. On clinic review nine months
later, she noticed a spontaneous, painful and discoloured
swelling of the left breast (Figure 1, left panel). This was
initially diagnosed as cellulitis and treated with antibiot-
ics, but as there was no improvement, a fine-needle aspi-
ration was carried out which showed no recurrence of the
breast cancer.
She was referred to a rheumatologist and dermatologist.
She was screened for systemic collagen disease and fungal
infection. By then, the abnormal area had extended fur-
ther to the axilla and medial aspect of the left upper arm.
A review of the breast radiotherapy plans and delivery did
not reveal any incorrect delivery or unexpected high sub-
cutaneous dose.
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Subsequent breast biopsies confirmed RIM of the breast.
The histology showed intact epidermis but the papillary
dermis had a patchy perivascular lymphocytic infiltrate.
The most striking changes were in the reticular dermis
where the collagen bundles appeared thickened with
increased eosinophilia, accompanied by a moderate
amount of chronic inflammatory cell infiltrate consisting
of lymphocytes predominantly, plasma cells and histio-
cytes (Figure 2).
Various treatments including topical and oral steroids and
oral psoralen ultraviolet-A (PUVA) therapy did not
improve the appearance of the breast. Paracetamol and
amitriptyline were used to control her breast pain. The
patient was referred to a plastic surgeon but she declined
any reconstructive surgery.
The photographs in Figure 1 show the changes in the left
breast over time. The initial appearance was of swelling,
erythema and bruising (Figure 1, left panel). It reduced in
size and became harder with skin telangiectasia over one
year (Figure 1, middle panel) and 3 and a half years post-
radiotherapy (Figure 1, right panel). On her clinical
review 6 and a half years post-radiotherapy, she remained
free from recurrence and the breast appearance did not
deteriorate any further.
Discussion
RIM of the breast is rare, with an estimated incidence of
0.20% [4]. Its onset ranges from 1 to 12 months [4,5], but
could be as late as 32 years post-radiotherapy [6]. Syno-
nyms include radiation port morphea, radiation-induced
scleroderma, radiation port scleroderma, post-irradiation
morphea, localised scleroderma and circumscribed sclero-
derma.
RIM can extend beyond the irradiated area. A patient with
breast cancer, with the confounding factors of endome-
trial cancer and pelvic radiotherapy 3 years prior, devel-
oped RIM in the breast, abdominal wall and leg at 2, 12
and 54 months respectively, following breast radiother-
apy [7].
RIM is not an exaggerated post-irradiation fibrosis of the
breast. Post-irradiation fibrosis is more common and is
primarily a deep subcutaneous and fascial fibrosis with lit-
tle or no inflammatory infiltrate [6]. In contrast, RIM is a
localised scleroderma of primarily dermal fibrosis (Figure
2) due to radiation-induced disturbance in the immune
system, vasculature and collagen metabolism. RIM has an
initial inflammatory phase and a subsequent 'burnt-out'
phase, where the latter displays induration, fibrotic retrac-
tion and pigmentation of the breast. The pathophysiology
of RIM is thought to be radiation-induced neoantigen for-
mation that subsequently stimulates secretion of trans-
Changes in the left breast over time Figure 1
Changes in the left breast over time. Nine months post-radiotherapy, the breast was erythematous, swollen and looked 
bruised (left panel). One year post-radiotherapy, the breast was retracted and pigmented (middle panel). Three and a half years 
post-radiotherapy, the breast had reduced in size and hardened with hypo- and hyper-pigmentation. The inframammary fold 
had significant skin telangiectasia (right panel).Journal of Medical Case Reports 2008, 2:136 http://www.jmedicalcasereports.com/content/2/1/136
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forming growth factor beta (TGF-β). TGF-β strongly
induces fibroblast activation, collagen synthesis and,
hence, excessive fibrosis [4,6].
There is no definite correlation between tamoxifen use
and the development of RIM. However, tamoxifen can
induce TGF-β secretion and increase lung fibrosis in breast
cancer patients receiving both tamoxifen and radiother-
apy [8].
Systemic sclerosis is a relative risk factor for developing an
exaggerated post-irradiation fibrosis, although this patient
had no previous history of systemic sclerosis. Age and
radiotherapy parameters such as total radiation dose, dose
per fraction and severity of acute reaction do not seem to
be significant risk factors for developing RIM [5].
Various treatments including oral antibiotics and topical,
intralesional or systemic steroids have been used in treat-
ing RIM of the breast with varying results [5]. One patient
had improvement without any treatment [6].
Morphea has been treated with topical and systemic ster-
oids, colchicine, D-penicillamine, immunosuppressants
and cytotoxics such as azathioprine, methotrexate, cyclo-
phosphamide and cyclosporin, plasmapheresis and extra-
corporeal photopheresis, with variable benefit [9].
PUVA therapy in 10 to 20 sessions for morphea has been
reported to cause remarkable skin softening associated
with a reduction in skin cytokines including TGF-β [9].
The mechanism of action of PUVA is attributed to the sup-
pression of inflammation and collagen mediators causing
a reduction in pruritus, pigmentation and skin tightness.
Histopathology slides showing lymphocytic infiltrate and thickened collagen bundles in the dermis Figure 2
Histopathology slides showing lymphocytic infiltrate and thickened collagen bundles in the dermis.Publish with BioMed Central    and   every 
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Any treatment modality should be started promptly to
give the best outcome, as fibrosis and atrophy are not
reversed by PUVA therapy. Early referral to a dermatolo-
gist is therefore recommended.
Reconstructive surgery for morphea of the breast has been
reported to give a good cosmetic result [10]. To the best of
the authors' knowledge, no surgery has yet been per-
formed for RIM of the breast.
Conclusion
Adjuvant radiotherapy following breast-conservation sur-
gery can reduce local recurrence and improve survival in
breast cancer patients. A late radiotherapy side effect in the
form of RIM of the breast is rare, but causes significant
morbidity and deformity. Clinicians need to be aware of
RIM after ruling out infection or recurrence of breast can-
cer, as RIM can mimic these conditions. There is no
proven treatment once the condition is established. There
are no reliable predictors for the development of RIM, and
its occurrence defeats the purpose of achieving good cos-
mesis in breast-conservation surgery.
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